# An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

> **NCT05835310** · PHASE3 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 100 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **BIOLOGICAL:** Anifrolumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05835310
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-14
- **Primary completion:** 2028-10-05
- **Final completion:** 2030-01-09
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05835310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05835310, "An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT05835310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*